Holen Sie sich die Stockscreener-App
6.67
8.46%
0.52
Handel nachbörslich:
6.62
-0.05
-0.75%
Schlusskurs vom Vortag:
$6.15
Offen:
$6.2
24-Stunden-Volumen:
1.41M
Relative Volume:
1.39
Marktkapitalisierung:
$308.99M
Einnahmen:
$20.72M
Nettoeinkommen (Verlust:
$-100.84M
KGV:
-2.5075
EPS:
-2.66
Netto-Cashflow:
$-78.56M
1W Leistung:
+16.40%
1M Leistung:
+55.84%
6M Leistung:
+41.31%
1J Leistung:
-55.35%
1-Tages-Spanne:
$6.15
$6.84
1-Wochen-Bereich:
$5.3301
$6.84
52-Wochen-Spanne:
$2.235
$17.41
4 D Molecular Therapeutics Inc Stock (FDMT) Company Profile
Firmenname
4 D Molecular Therapeutics Inc
Sektor
Branche
Telefon
(510) 505-2680
Adresse
5858 HORTON STREET #455, EMERYVILLE
Vergleichen Sie FDMT mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
FDMT
4 D Molecular Therapeutics Inc
|
6.67 | 256.18M | 20.72M | -100.84M | -78.56M | -2.66 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.92 | 99.42B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.55 | 58.99B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
432.52 | 56.35B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
646.60 | 39.02B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
307.51 | 34.25B | 3.81B | -644.79M | -669.77M | -6.24 |
4 D Molecular Therapeutics Inc Stock (FDMT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-01-13 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2024-11-21 | Eingeleitet | Morgan Stanley | Underweight |
| 2024-09-23 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2024-04-15 | Eingeleitet | Barclays | Overweight |
| 2024-02-07 | Fortgesetzt | Goldman | Buy |
| 2023-10-26 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2023-10-24 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-10-18 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2023-07-05 | Eingeleitet | Chardan Capital Markets | Buy |
| 2023-01-30 | Eingeleitet | BMO Capital Markets | Outperform |
| 2022-11-18 | Eingeleitet | H.C. Wainwright | Buy |
| 2022-11-15 | Hochstufung | Goldman | Neutral → Buy |
| 2022-08-12 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2022-06-22 | Eingeleitet | Jefferies | Buy |
| 2022-01-04 | Eingeleitet | SVB Leerink | Outperform |
| 2021-01-05 | Eingeleitet | BofA Securities | Buy |
| 2021-01-05 | Eingeleitet | Evercore ISI | Outperform |
| 2021-01-05 | Eingeleitet | Goldman | Neutral |
Alle ansehen
4 D Molecular Therapeutics Inc Aktie (FDMT) Neueste Nachrichten
Can trapped investors hope for a rebound in 4D Molecular Therapeutics Inc.Market Activity Summary & AI Optimized Trading Strategy Guides - Newser
Is 4D Molecular Therapeutics Inc. meeting your algorithmic filter criteria2025 Fundamental Recap & Capital Protection Trading Alerts - Newser
4D Molecular Therapeutics (NASDAQ:FDMT) Receives “Buy” Rating from Chardan Capital - Defense World
Can you recover from losses in 4D Molecular Therapeutics Inc.Risk Aware Trading Ideas with Alert Levels - Newser
What makes 4D Molecular Therapeutics Inc. stock price move sharplyRisk Aware Trading Ideas with Alert Levels - Newser
How 4D Molecular Therapeutics Inc. stock performs during market volatilityHigh Return Strategy with Low Risk - Newser
Using AI based signals to follow 4D Molecular Therapeutics Inc.Consistent Gain Plan with AI Support - Newser
Is 4D Molecular Therapeutics Inc. forming a reversal patternFundamental + Technical Combined Watchlist - Newser
Chardan Capital Raises PT on 4D Molecular to $25. - AInvest
4D Molecular Therapeutics Faces Revenue Challenges Amid Complex Reimbursement Landscape - TipRanks
Published on: 2025-08-12 01:26:37 - Newser
Will earnings trigger a reversal in 4D Molecular Therapeutics Inc.Free Pattern Breakout Entry Stock Forecast - Newser
4D Molecular Therapeutics Advances Clinical Programs in Q2 2025 - TipRanks
4D Molecular Therapeutics, Inc. (FDMT) Reports Q2 Loss, Misses Revenue Estimates - sharewise.com
4D Molecular Therapeutics Tightens Belt While Chasing FDA Approval - Finimize
Spectral Ai, Inc. shares rise 1.64% premarket after 4D Molecular Therapeutics reported positive 60-week results from 4D-150 SPECTRA clinical trial in DME. - AInvest
4d Molecular Therapeutics Posts Q2 2025 Revenue Surge of 200% to $15 Million - AInvest
4D Molecular Therapeutics: Is the Widening Net Loss Justified by the Promise of 4D-150 in Wet AMD? - AInvest
4dMT Revenue Jumps 200 Percent in Q2 - The Motley Fool
4D Molecular Therapeutics, Inc. SEC 10-Q Report - TradingView
4D Molecular Therapeutics Reports Q2 GAAP EPS of -$0.98, Below Expectations - AInvest
4D Molecular Therapeutics Q2 net loss widens to $54.7 mln - MarketScreener
4D Molecular Therapeutics advances 4D-150 program, extends cash runway to 2028. - AInvest
4DMT Reports Second Quarter 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones - GlobeNewswire
4DMT Fast-Tracks Wet AMD Phase 3 Trial: Key Data Now Expected 6 Months Earlier Than Planned - Stock Titan
Developing predictive dashboards with 4D Molecular Therapeutics Inc. dataWeekly Entry Signal Based Forecast Tool - Newser
Volatility clustering patterns for 4D Molecular Therapeutics Inc.Free Swing Trade With Risk Management - Newser
Will 4D Molecular Therapeutics Inc. price bounce be sustainableFree Smart Money Tracking Signal Generator - Newser
4D Molecular Therapeutics Inc. stock prediction for this weekShort-Term Stock Trend Forecast Guide - Newser
Why 4D Molecular Therapeutics Inc. stock attracts strong analyst attentionMulti-Bagger Detection with Trend Tools - Newser
How to build a custom watchlist for 4D Molecular Therapeutics Inc.Free Price Action Based Buy Opportunity List - Newser
What technical models suggest about 4D Molecular Therapeutics Inc.’s comebackConsistent Gain Plan with AI Support - Newser
Technical analysis overview for 4D Molecular Therapeutics Inc. stockFree Portfolio Diversification Stock Ideas - Newser
Heatmap analysis for 4D Molecular Therapeutics Inc. and competitorsFree Momentum Based Equity Trading Plan - Newser
What makes 4D Molecular Therapeutics Inc. stock attractive to long term investorsFree Real Market Momentum Signal Generator - Newser
4D Molecular Therapeutics to Participate in H.C. Wainwright Ophthalmology Virtual Conference - AInvest
4D Molecular Therapeutics shares fall 1.92% premarket ahead of H.C. Wainwright 5th Annual Ophthalmology Virtual Conference. - AInvest
4D Molecular Therapeutics (FDMT) to Release Earnings on Thursday - Defense World
4D Molecular Therapeutics shares fall 2.73% intraday after announcing participation in H.C. Wainwright 5th Annual Ophthalmology Virtual Conference. - AInvest
Using fundamentals and technicals on 4D Molecular Therapeutics Inc.AI Volatility Forecast and Risk Monitor - Newser
4D Molecular Therapeutics Inc expected to post a loss of 88 cents a shareEarnings Preview - TradingView
Fibonacci Support Holding Strong in 4D Molecular Therapeutics Inc.Conservative Long Term Growth Plans Under Review - beatles.ru
Why is 4D Molecular Therapeutics Inc. stock attracting strong analyst attentionAchieve consistent profits with proven methods - Jammu Links News
4D Molecular Therapeutics’ (FDMT) Buy Rating Reiterated at Chardan Capital - Defense World
Is 4D Molecular Therapeutics Inc. a growth stock or a value stockProven strategies for superior portfolio growth - Jammu Links News
Finanzdaten der 4 D Molecular Therapeutics Inc-Aktie (FDMT)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.67%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):